The purpose of this study is to test the safety and effectiveness of Losartan potassium in
subjects with Eosinophilic Esophagitis (EoE), both those with a connective tissue disorder
(CTD) and those without a CTD.
Drug: Losartan Potassium
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT03029091
Ages eligible for Study
5 Years to 25 Years
Genders eligible for Study
Accepts Healthy Volunteers
Written informed consent/assent
confirmed, active EoE (at Screening or within 12 weeks prior to enrollment)
does or does not have diagnosis of a connective tissue disorder (CTD)
has been on a high dose of proton pump inhibitor (PPI) for at least 8 weeks prior to a diagnostic endoscopy of EoE without histologic resolution (i.e., ≥ 15 eosinophils/HPF).
maintain the same diet throughout the duration of the study
female participants must be either:
of non-childbearing potential (pre-menarchal or surgically sterile with documentation). OR
have a negative urine pregnancy test at screening and at each monthly study visit.
Any past or planned cardiac surgery.
An aortic root Z-score ≥ 3.0 on a previous echocardiogram.
Intolerance to losartan
A mean blood pressure measurement (both systolic and diastolic) at screening that is below the 2nd percentile for his/her age
Another disorder that causes esophageal eosinophilia (e.g., hypereosinophilic syndrome, Churg Strauss vasculitis, eosinophilic granuloma, or a parasitic infection).
A diagnosis of hepatic insufficiency.
A history of abnormal gastric or duodenal biopsy or documented gastrointestinal disorders (e.g., Celiac Disease, Crohn's disease or Helicobacter pylori infection), not including chronic gastritis, chronic duodenitis, mucosal eosinophilia or other eosinophilic gastrointestinal disorders (EGIDs).
Use of anti-IgE monoclonal antibody (mAb), anti-tumor necrosis factor [TNF] mAb, anti-IL-5 agents, or anti-IL-13 within 6 months prior to study entry
Use of methotrexate, cyclosporine, interferon α, or other systemic immunosuppressive or immunomodulating agents within 3 months prior to the screening visit.
A stricture during endoscopy procedure that prevents passage of the endoscope
Taking or is planning to take an angiotensin receptor blocker (ARB), angiotensin-converting enzyme inhibitor (ACEI), beta blocker (BB), or calcium-channel blocker therapy at the screening visit or at any time during the study or has been taking any of these medications for 3 months prior to the screening visit.
Taking or planning to take hydrochlorothiazide, digoxin, warfarin, cimetidine, phenobarbital, rifampin, or fluconazole.
taking or planning to take potassium supplements or salt substitutes containing potassium.
A female participant who is pregnant or nursing or, if of childbearing potential, is not using a medically accepted, effective method of birth control (e.g., condom, oral/injectable/subcutaneous contraceptive, intrauterine device, or sexual abstinence).
Participated/participating in any investigative drug or device study within 30 days prior to study entry.
Participated/participating in any investigative biologics study within 3 months prior to study entry.
Unable to be confirmed, active EoE (at Screening or within 12 weeks prior to enrollment)
All locations for NCT03029091
United States (3)
University of California, San Diego
La Jolla, California, United States, 92093
not yet recruiting
Chicago, Illinois, United States, 60208
not yet recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Put me in touch!
View full eligibility
Tris trial is registered with FDA with number: NCT03029091. The sponsor of the trial is Children's Hospital Medical Center, Cincinnati and it is looking for 15 volunteers for the current phase.
Official trial title: A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!